HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MDB5

hedgehog (Hh) signaling pathway inhibitor

Also Known As:

2-chloro-N 1-(4-chloro-3-(2-pyridinyl)phenyl)-N 4,N 4- bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide

Networked: 4 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        MDB5: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - MDB5: 4

Experts

1.	Dong, Yuxiang: 4 articles (11/2021 - 10/2017)
2.	Mahato, Ram I: 4 articles (11/2021 - 10/2017)
3.	Kumar, Vinod: 3 articles (11/2021 - 10/2017)
4.	Kumar, Virender: 3 articles (11/2021 - 10/2017)
5.	Lin, Feng: 2 articles (11/2021 - 10/2017)
6.	Coulter, Donald W: 1 article (11/2021)
7.	Sethi, Bharti: 1 article (11/2021)
8.	Wang, Qiyue: 1 article (11/2021)
9.	Almawash, Saud: 1 article (01/2019)
10.	Chen, Hao: 1 article (01/2019)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2019 - "We have designed a novel microtubule destabilizer (2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (QW-296) and combined it with a newly synthesized hedgehog (Hh) signaling pathway inhibitor 2-chloro-N 1-[4-chloro-3-(2-pyridinyl)phenyl]-N 4,N 4- bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide (MDB5) to treat taxane-resistant (TXR) prostate cancer. " 01/01/2019 - "The overall findings suggest that combination therapy with QW-296 and MDB5 has great clinical potential to treat TXR prostate cancer, and copolymer mPEG-p(TMC-MBC) could serve as an effective delivery vehicle to boost therapeutic efficacy in vivo."
2.	Liver Cirrhosis (Hepatic Cirrhosis) 01/01/2019 - "We evaluated the therapeutic efficacy of MDB5 loaded micelles in common bile duct ligation (CBDL) induced liver fibrosis, mouse model. "
3.	Neoplasms (Cancer) 10/01/2017 - "In a pancreatic tumor mouse model, MDB5 containing nanoparticles treated group showed significant inhibition of tumor growth without loss in body weight. " 11/01/2021 - "Moreover, systemic administration of COG-133-NPs loaded with MDB5 and SF2523 resulted in decreased tumor burden compared to non-targeted drug-loaded NPs, without any hepatic toxicity. " 01/01/2019 - "The combination of QW-296 and MDB5 exhibited stronger anticancer activity toward DU145-TXR and PC3-TXR cells and suppressed tumor colony formation when compared with single-drug treatment. " 01/01/2019 - "There was maximum tumor growth inhibition in the group treated with the combination therapy of QW-296 and MDB5 in micelles compared with their monotherapies or combination therapy formulated in cosolvent. "
4.	Body Weight (Weight, Body) 10/01/2017 - "In a pancreatic tumor mouse model, MDB5 containing nanoparticles treated group showed significant inhibition of tumor growth without loss in body weight. "

Related Drugs and Biologics

1.	Micelles
2.	monomethoxypolyethylene glycol (MPEG)
3.	QW-296
4.	taxane
5.	SF2523

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation